Abstract
Cannabis-based medicinal products (CBMPs) were approved for use by specialist medical practitioners in the UK in 2018. Licensed indications for CBMPs are limited, but studies have suggested potential benefits from...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Neurology, Neurosurgery & Psychiatry
Paper Title
Journal
Date
